The effective concentration required for 50% maximal binding (EC50, μg/mL) for each of the mAbs was calculated by using sigmoidal four-parameter nonlinear regression in Prism with log-transformed mAb
This project contains the underlying data included in a study which characterized six commercially available antibodies for ARID2. The original study is also available on the Zenodo YCharOS community